Position in ALVO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$23,348
+$21,743 QoQ
Shares Held
6,807
+2074.8% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ALVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Larson Financial Group LLC holds $2,020,512 across 41 Drug Manufacturers - Specialty & Generic names. ALVO ranks #14 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
6,129 | $724,509 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
1,542 | $203,143 | |
| 3 | TAK |
Takeda Pharmaceutical Co Ltd
|
7,759 | $143,696 | |
| 4 | HIMS |
Hims & Hers Health, Inc.
|
6,697 | $139,029 | |
| 5 | HLN |
Haleon plc
|
12,224 | $122,362 | |
| 6 | LNTH |
Lantheus Holdings, Inc.
|
1,453 | $110,210 | |
| 7 | UTHR |
UNITED THERAPEUTICS Corp
|
181 | $107,329 | |
| 8 | HROW |
Harrow, Inc.
|
2,277 | $80,287 |
All Filings in ALVO
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $23,348 | 6,807 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,605 | 313 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $1,539 | 188 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $446 | 49 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $290 | 30 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $396 | 30 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $357 | 30 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $364 | 30 | Shares | Sole | 2024-08-02 | |
| 2024-03-31 | $366 | 30 | Shares | Sole | 2024-05-03 | |
| 2023-12-31 | $344 | 30 | Shares | Sole | 2024-02-01 | |
| No filing history on record for this holder in this stock. | ||||||